Eficacia y seguridad clínica del itolizumab en fase de inducción, en pacientes con psoriasis grave
Introducción: La psoriasis, enfermedad inflamatoria sistémica de la piel, tiene consecuencias adversas serias para el bienestar físico, mental y social de las personas; sus tratamientos son costosos y con marcados efectos adversos. El itolizumab, anticuerpo monoclonal anti CD6 humanizado, actúa como...
Main Authors: | Martiza Batista Romagosa, Olaine Regla Gray Lovio, Leopoldina Falcón Lincheta, Teresita Pérez Alonso, Beatriz Mantecón Fernández, Aleida Urquiza Rodríguez, Liliana Almenares Soria, Yaimarelis Saumell Nápoles, Ana Rosa Valls Hung |
---|---|
Format: | Article |
Language: | Spanish |
Published: |
ECIMED
2020-04-01
|
Series: | Revista Cubana de Medicina Militar |
Subjects: | |
Online Access: | http://revmedmilitar.sld.cu/index.php/mil/article/view/477 |
Similar Items
-
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
by: Ganesh Pai, et al.
Published: (2017-08-01) -
Itolizumab in psoriasis
by: Ankita Srivastava
Published: (2017-01-01) -
A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis
by: Anchala Parthasaradhi, et al.
Published: (2017-01-01) -
Safety and Efficacy of Itolizumab in the Treatment of Psoriasis: A Case Series of 20 Patients
by: Anchala Parthasaradhi
Published: (2016-11-01) -
An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
by: Danay Saavedra, et al.
Published: (2020-11-01)